Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures

Dermatol Ther. 2021 Nov;34(6):e15116. doi: 10.1111/dth.15116. Epub 2021 Sep 7.

Authors

Raffaele Dante Caposiena Caro¹, Chiara Pensa², Sara Lambiase², Eleonora Candi¹, Luca Bianchi²

Affiliations

¹ Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
² Dermatology Department, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

PMID: 34459075
DOI: 10.1111/dth.15116

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / adverse effects
Hidradenitis Suppurativa* / diagnosis
Hidradenitis Suppurativa* / drug therapy
Humans
Tumor Necrosis Factor Inhibitors*

Substances

Antibodies, Monoclonal
Tumor Necrosis Factor Inhibitors
risankizumab